Marine Biomedical
PrivateLast Round
Strategic
Jan 16, 2026
Total Funding Raised
$3.15M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Marine Biomedical operates in Healthcare & Life Sciences and is based in Broome. Its latest recorded funding round was a Strategic round in January 2026.
Marine Biomedical is a biotechnology company that develops and manufactures marine-derived biomaterials, including its flagship bone substitute product PearlBone™, for use in orthopaedic and dental applications.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices, Advanced Materials, Circular Economy, Sustainable Materials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Marine Biomedical Comparables
Compare Marine Biomedical with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| CoreBone | 83% | |
| Zoan BioMed | 82% | |
| Molecular Matrix, Inc. | 78% |
For institutional investors. Book with your work email.
Marine Biomedical Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Jan 16, 2026 | ||||
| Early Funding | May 1, 2025 | ||||
| Grant | May 17, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Marine Biomedical Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Government of Western Australia | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 1, 2026
Monthly visitors grew 251% MoM, reaching 842.
- Jan 16, 2026
$740K raised, led by Orthocell Ltd
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingNov 3, 2026
Marine Biomedical Pty Ltd. receives a $1.05M equity investment from Orthocell, which holds a 12 per cent equity interest and secures a first right of refusal over global distribution rights for PearlBone and future bone repair products.
- receives_financingNov 2, 2026
Marine Biomedical Pty Ltd. receives a strategic investment equivalent to $738K, giving the investor a 12% equity interest and a first right of refusal over global distribution rights for PearlBone(TM) and future bone repair products.
For institutional investors. Book with your work email.
Marine Biomedical Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Marine Biomedical's valuation, stock price, and market status.
Is Marine Biomedical a public or private company?
Marine Biomedical is a private company.
What is the current stock price of Marine Biomedical?
Marine Biomedical is a private company, so its shares have no public market price. Caplight tracks Marine Biomedical's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Marine Biomedical worth (valuation)?
Valuation information for Marine Biomedical is not publicly available.
Can I buy Marine Biomedical stock?
Marine Biomedical shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Marine Biomedical's last funding round?
Marine Biomedical's most recent funding round was Strategic on January 16, 2026.
Who are the main investors in Marine Biomedical?
Key investors in Marine Biomedical include Government of Western Australia.
Will Marine Biomedical IPO soon?
No public IPO plans have been announced for Marine Biomedical.
How can I track Marine Biomedical secondary market activity?
Caplight tracks bids, offers, and trades in Marine Biomedical's shares on secondary markets.